Monte Rosa Therapeutics Inc (GLUE)vsBeOne Medicines AG (ONC)
GLUE
Monte Rosa Therapeutics Inc
$8.64
-3.03%
HEALTHCARE · Cap: $880.99M
ONC
BeOne Medicines AG
$390.94
-2.19%
HEALTHCARE · Cap: $45.66B
Smart Verdict
WallStSmart Research — data-driven comparison
BeOne Medicines AG generates 9294% more annual revenue ($6.61B vs $70.33M). ONC leads profitability with a 13.9% profit margin vs -186.2%. ONC earns a higher WallStSmart Score of 68/100 (B-).
GLUE
Hold36
out of 100
Grade: F
ONC
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GLUE.
Margin of Safety
+80.8%
Fair Value
$1828.58
Current Price
$390.94
$1437.64 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 325.8% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Revenue surging 33.8% year-over-year
Earnings expanding 212.5% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.4% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : GLUE
The strongest argument for GLUE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 325.8% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 33.8% demonstrates continued momentum. PEG of 0.71 suggests the stock is reasonably priced for its growth.
Bear Case : GLUE
The primary concerns for GLUE are EPS Growth, Market Cap, Return on Equity.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 51.2x leaves little room for execution misses.
Key Dynamics to Monitor
GLUE profiles as a hypergrowth stock while ONC is a growth play — different risk/reward profiles.
GLUE carries more volatility with a beta of 1.38 — expect wider price swings.
GLUE is growing revenue faster at 325.8% — sustainability is the question.
ONC generates stronger free cash flow (474M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (68/100 vs 36/100) and 33.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Monte Rosa Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.
Visit Website →BeOne Medicines AG
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?